NFKB1 and atherosclerosis: ZL, in combination with atorvastatin, can inhibit the activation of the NF-κB/NLRP3 signaling pathway and limit the release of p-NF-κB, NLRP3, caspase-1, IL-1β, and IL-18, thereby alleviating vascular inflammation and significantly attenuating atherosclerosis in rabbits [36].